RxSight, Inc. (RXST)
2025-06-30 | 2025-03-31 | 2024-09-30 | ||
|---|---|---|---|---|
| Sales | 33,637 | 37,895 | 35,314 | |
| Cost of sales | 8,447 | 9,566 | 10,094 | |
| Gross profit | 25,190 | 28,329 | 25,220 | |
| Selling, general and administrative | 28,976 | 28,636 | 25,608 | |
| Research and development | 10,217 | 10,367 | 8,838 | |
| Total operating expenses | 39,193 | 39,003 | 34,446 | |
| Loss from operations | -14,003 | -10,674 | -9,226 | |
| Interest expense | 5 | 6 | 5 | |
| Interest and other income | 2,254 | 2,508 | 2,906 | |
| Loss before income taxes | -11,754 | -8,172 | -6,325 | |
| Income tax expense | 32 | 18 | 13 | |
| Net loss | -11,786 | -8,190 | -6,338 | |
| Foreign currency translation gain (loss) | 14 | 6 | 6 | |
| Unrealized loss on short-term investments | -146 | -157 | 633 | |
| Total other comprehensive loss | -132 | -151 | 639 | |
| Comprehensive loss | -11,918 | -8,341 | -5,699 | |
| Earnings per share, basic | -0.29 | -0.2 | -0.16 | |
| Earnings per share, diluted, total | -0.29 | -0.2 | -0.16 | |
| Weighted average number of shares outstanding, basic, total | 40,743,786 | 40,509,646 | 39,788,621 | |
| Weighted average number of shares outstanding, diluted | 40,743,786 | 40,509,646 | 39,788,621 | |